A Case of Metastatic Urothelial Carcinoma with Pseudoprogression of Liver Metastasis during the Treatment with Pembrolizumab

DOI HANDLE Web Site Open Access
  • MASUDA Hiroo
    The Department of Urology, Osaka City University, Graduate School of Medicine
  • KATO Minoru
    The Department of Urology, Osaka City University, Graduate School of Medicine
  • YOSHIUCHI Hiroki
    The Department of Urology, Yao Municipal Hospital
  • YUKIMATSU Nao
    The Department of Urology, Osaka City University, Graduate School of Medicine
  • HIRAYAMA Yukiyoshi
    The Department of Urology, Osaka City University, Graduate School of Medicine
  • OTOSHI Taiyo
    The Department of Urology, Osaka City University, Graduate School of Medicine
  • YAMASAKI Takeshi
    The Department of Urology, Osaka City University, Graduate School of Medicine
  • KURATSUKURI Katsuyuki
    The Department of Urology, Osaka City University, Graduate School of Medicine
  • UCHIDA Junji
    The Department of Urology, Osaka City University, Graduate School of Medicine

Bibliographic Information

Other Title
  • ペムブロリズマブ投与中に肝転移のPseudoprogressionを認めた転移性尿路上皮癌の1例
  • ペムブロリズマブ トウヨ チュウ ニ カン テンイ ノ Pseudoprogression オ ミトメタ テンイセイ ニョウロ ジョウヒガン ノ 1レイ

Search this article

Abstract

A 75-year-old woman with a complaint of gross hematuria was referred to our hospital. The patient was diagnosed as having bladder cancer (cT3bN1M0) and received two cycles of chemotherapy with gemcitabine and cisplatin. Radical cystectomy with pelvic lymph node dissection and bilateral ureterostomy was performed after achieving partial response in a lymph node metastasis following chemotherapy. Based on the pathological diagnosis of high-grade (G3) urothelial carcinoma (ypT3aN2), two more cycles of adjuvant chemotherapy with gemcitabine and cisplatin were administered. Four months after completing adjuvant chemotherapy, pulmonary and hepatic metastases appeared, and treatment with pembrolizumab was initiated. The size of the lung metastasis decreased, while that of the liver metastasis increased 2 months after administering pembrolizumab. However, considering treatment beyond progression using checkpoint inhibitors, pembrolizumab was continued, resulting in marked tumor shrinkage of the liver metastasis. After that, pembrolizumab treatment was temporarily discontinued, and radiation therapy was administered for a new lymph node metastasis at the tracheal bifurcation. Eventually, the lymph node metastasis shrank, and the treatment with pembrolizumab was recommenced for 1 year and the metastases remained shrumken.

Journal

  • 泌尿器科紀要

    泌尿器科紀要 68 (4), 117-121, 2022-04-30

    泌尿器科紀要刊行会

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top